PET Imaging of 68Ga-Her2-affibody in Tumors with High Her2 Expression

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

July 30, 2025

Study Completion Date

August 30, 2025

Conditions

Neoplasms

Interventions

DRUG

68Ga-Her2-affibody

68Ga-Her2-affibody is injected intravenously with a dose of 0.06-0.08 mCi/kg.

Trial Locations (1)

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors

lead

Peking University First Hospital

OTHER